MedPath

The effect of pentoxifylline on ventricular arrhythmia

Phase 3
Recruiting
Conditions
Ventricular arrhythmia.
Paroxysmal tachycardia
Registration Number
IRCT20220516054874N16
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
72
Inclusion Criteria

Age older than 18 years old
Heart failure diagnosis
ICD implantation > 6 months before eligibility test
Signed written informed consent to participate in the study

Exclusion Criteria

Using Pentoxifylline or other methyl Methylxanthines
New York Heart Association Class IV heart failure
Renal dysfunction with eGFR < 30
Hepatic dysfunction
Body mass index < 18.5 kg/m2
Pregnant or suspected pregnancy
Patients with the following events within 3months before the eligibility test: alteration of antiarrhythmic drug, catheter ablation for ventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization, heart failure requiring hospitalization
Other comorbidities including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, cancer
ICDs unable to record cardiac arrhythmias

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath